These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 35177833)

  • 1. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.
    Karran E; De Strooper B
    Nat Rev Drug Discov; 2022 Apr; 21(4):306-318. PubMed ID: 35177833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein aggregation in Alzheimer's disease: Aβ and τ and their potential roles in the pathogenesis of AD.
    Thal DR; Fändrich M
    Acta Neuropathol; 2015 Feb; 129(2):163-5. PubMed ID: 25600324
    [No Abstract]   [Full Text] [Related]  

  • 5. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
    Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
    Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation.
    Luan K; Rosales JL; Lee KY
    Ageing Res Rev; 2013 Jan; 12(1):174-81. PubMed ID: 22728532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased tauopathy drives microglia-mediated clearance of beta-amyloid.
    Chen W; Abud EA; Yeung ST; Lakatos A; Nassi T; Wang J; Blum D; Buée L; Poon WW; Blurton-Jones M
    Acta Neuropathol Commun; 2016 Jun; 4(1):63. PubMed ID: 27339073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β-independent regulators of tau pathology in Alzheimer disease.
    van der Kant R; Goldstein LSB; Ossenkoppele R
    Nat Rev Neurosci; 2020 Jan; 21(1):21-35. PubMed ID: 31780819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation.
    Ashrafian H; Zadeh EH; Khan RH
    Int J Biol Macromol; 2021 Jan; 167():382-394. PubMed ID: 33278431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical analysis of the 'amyloid cascade hypothesis'.
    Armstrong RA
    Folia Neuropathol; 2014; 52(3):211-25. PubMed ID: 25310732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease.
    Morris GP; Clark IA; Vissel B
    Acta Neuropathol Commun; 2014 Sep; 2():135. PubMed ID: 25231068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease.
    Tomita T
    Adv Biol Regul; 2017 May; 64():33-38. PubMed ID: 28082052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy.
    van Helmond Z; Miners JS; Kehoe PG; Love S
    Brain Pathol; 2010 Mar; 20(2):468-80. PubMed ID: 19725829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous Murine Amyloid-β Peptide Assembles into Aggregates in the Aged C57BL/6J Mouse Suggesting These Animals as a Model to Study Pathogenesis of Amyloid-β Plaque Formation.
    Ahlemeyer B; Halupczok S; Rodenberg-Frank E; Valerius KP; Baumgart-Vogt E
    J Alzheimers Dis; 2018; 61(4):1425-1450. PubMed ID: 29376876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.